Abstract
* Sodium-glucose cotransporter-2 (SGLT2) inhibitors, used to treat type 2 diabetes, may lead to diabetic ketoacidosis, ketoacidosis, or ketosis early in drug therapy. The class includes canagliflozin, dapagliflozin, and empagliflozin.
* Patients beginning treatment with an SGLT2 inhibitor should be instructed to be alert for tachypnea or hyperventilation, anorexia, abdominal pain, nausea, vomiting, lethargy, or mental status changes.